Novel drug combinations and targeted therapies show promise for patients with leukemia
Researchers from The University of Texas MD Anderson Cancer Center are presenting compelling findings from three clinical trials at the 2022 American Society of Hematology (ASH) Annual Meeting. These oral presentations highlight encouraging results to advance the use of targeted therapies and novel combinations in multiple types of leukemia, including high-risk and newly diagnosed acute myeloid leukemia (AML) in older and younger patients...
MD Anderson’s Christopher Flowers, M.D., receives ASH Mentor Award
Christopher Flowers, M.D., division head ad interim of Cancer Medicine and chair of Lymphoma & Myeloma at The University of Texas MD Anderson...